Decisions 10th September 2013

Recent JFG Decisions


At the meeting on the 10th September 2013 the following decisions / changes to the formulary were agreed


New Drug Requests



  • Approved for inclusion, TLS Green, first line.


  • Approved for inclusion in the JF for the dietary management of water soluble vitamin deficiency in patients with chronic kidney disease in place of Dialyvit.  TLS blue for patients on renal dialysis.


Not approved


  • Rejected as the clinical evidence did not support the inclusion into the formulary although the JFG acknowledged that this was a novel drug and there would be an emerging evidence base.




  • The JFG was unable to consider the application fully due to insufficient clinical evidence provided at this time. 


  • The JFG was unable to consider the application fully due to insufficient clinical evidence provided.


Specialised Commissioning

  • No new statements


Shared Care Protocols

Methotrexate in Dermatology

  •  new SCP

Hydroxychloroquine in Dermatology

  • new SCP


Change in TLS


  • change in TLS status from amber to blue on the advice of a specialist service


Tapentadol MR for chronic pain

  • change form TLS Red to TLS amber once SCP is finalised


Insulin Degludec  

  • request for change from TLS red to amber was not approved


Other Decisions

  • Natamycin - is commissioned by the CCG, UHB to submit a NDR



Last updated by: on 11-11-2013 14:47